Bibliography for MD7511 Injectable Therapies BETA

: ‘Summary of Revisions’ (2016) Diabetes Care, 39(Supplement 1), pp. S4–S5. Available at: https://doi.org/10.2337/dc16-S003.

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes (no date). Available at: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html.

Akram, J., De Verga, V. and Group, the R.S. (1999) ‘Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan’, Diabetic Medicine, 16(10), pp. 867–874. Available at: https://doi.org/10.1046/j.1464-5491.1999.00164.x.

Aldam, P., Levy, N. and Hall, G.M. (2014) ‘Perioperative management of diabetic patients: new controversies’, British Journal of Anaesthesia, 113(6), pp. 906–909. Available at: https://doi.org/10.1093/bja/aeu259.

Ali, S. et al. (2016) ‘Guidelines for managing diabetes in Ramadan’, Diabetic Medicine, 33(10), pp. 1315–1329. Available at: https://doi.org/10.1111/dme.13080.

Anderson, B., Funnell, M., and American Diabetes Association (2005) The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandria, Va: American Diabetes Association.

Anderson, J.W., Kendall, C.W.C. and Jenkins, D.J.A. (2003) ‘Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies’, Journal of the American College of Nutrition, 22(5), pp. 331–339. Available at: https://doi.org/10.1080/07315724.2003.10719316.

Ashwell, S.G. et al. (2006) ‘Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes’, Diabetic Medicine, 23(3), pp. 285–292. Available at: https://doi.org/10.1111/j.1464-5491.2005.01781.x.

Bailey, S. (2011) Academic writing: a handbook for international students. 3rd ed. London: Routledge. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=310467.

Bajwa, S. et al. (2015) ‘Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care’, Journal of Anaesthesiology Clinical Pharmacology, 31(2). Available at: https://doi.org/10.4103/0970-9185.155141.

Bakiner, O. et al. (2009) ‘Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan’, Acta Diabetologica, 46(1), pp. 63–65. Available at: https://doi.org/10.1007/s00592-008-0062-7.

Barker, P. et al. (2015) ‘Peri-operative management of the surgical patient with diabetes 2015’, Anaesthesia, 70(12), pp. 1427–1440. Available at: https://doi.org/10.1111/anae.13233.

‘Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia’ (2012) New England Journal of Medicine, 367(4), pp. 319–328. Available at: https://doi.org/10.1056/NEJMoa1203858.

Benkhadra, K. et al. (2016) ‘Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis’, Clinical Endocrinology [Preprint]. Available at: https://doi.org/10.1111/cen.13290.

Bergenstal, R.M. et al. (2008) ‘Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine’, Diabetes Care, 31(7), pp. 1305–1310. Available at: https://doi.org/10.2337/dc07-2137.

Bergenstal, R.M. et al. (2010) ‘Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes’, New England Journal of Medicine, 363(4), pp. 311–320. Available at: https://doi.org/10.1056/NEJMoa1002853.

Bergenstal, R.M. et al. (2012) ‘A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes’, Diabetes Care, 35(11), pp. 2140–2147. Available at: https://doi.org/10.2337/dc12-0060.

Bretzel, R.G. et al. (2008) ‘Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial’, The Lancet, 371(9618), pp. 1073–1084. Available at: https://doi.org/10.1016/S0140-6736(08)60485-7.

Burnett, J.C.D. (2006) ‘Long‐ and Short‐Haul Travel by Air: Issues for People With Diabetes on Insulin’, Journal of Travel Medicine, 13(5), pp. 255–260. Available at: https://doi.org/10.1111/j.1708-8305.2006.00057.x.

Buse, J.B. et al. (2011) ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, 154(2). Available at: https://doi.org/10.7326/0003-4819-154-2-201101180-00300.

Buse, J.B. et al. (2014) ‘Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)’, Diabetes Care, 37(11), pp. 2926–2933. Available at: https://doi.org/10.2337/dc14-0785.

‘Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation’ (no date). Available at: http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-11.

Crasto, W. et al. (2009) ‘Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus’, Postgraduate Medical Journal, 85(1002), pp. 219–222. Available at: https://doi.org/10.1136/pgmj.2008.073379.

Crasto, W. (2016a) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Crasto, W. (2016b) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Crasto, W. (2016c) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Crasto, W. (2016d) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Crasto, W. (2016e) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Crasto, W. (2016f) Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition. Available at: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975.

Daly, H. et al. (2015) ‘Development of a self-management education module for those with type 2 diabetes on injectable therapies’, Practical Diabetes, 32(8), pp. 305–310a. Available at: https://doi.org/10.1002/pdi.1979.

Davies, M. et al. (2005a) ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine’, Diabetes Care, 28(6), pp. 1282–1288. Available at: https://doi.org/10.2337/diacare.28.6.1282.

Davies, M. et al. (2005b) ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine’, Diabetes Care, 28(6), pp. 1282–1288. Available at: https://doi.org/10.2337/diacare.28.6.1282.

Davies, M.J. et al. (2009) ‘Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study’, Diabetes, Obesity and Metabolism, 11(12), pp. 1153–1162. Available at: https://doi.org/10.1111/j.1463-1326.2009.01154.x.

Davies, M.J. et al. (2014) ‘Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial’, Diabetes, Obesity and Metabolism, 16(10), pp. 922–930. Available at: https://doi.org/10.1111/dom.12298.

Davies, M.J. et al. (2017) ‘Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents’, Diabetes, Obesity and Metabolism [Preprint]. Available at: https://doi.org/10.1111/dom.12980.

Davies, M.J. and Chatterjee, S. (2017) ‘Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care’, Nature Reviews Endocrinology, 13(6), pp. 317–318. Available at: https://doi.org/10.1038/nrendo.2017.41.

Diabetes & Metabolism - Présentation - EM consulte (no date). Available at: http://www.em-consulte.com/article/80031/alertePM#N1010C.

Diamant, M. et al. (2010) ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, 375(9733), pp. 2234–2243. Available at: https://doi.org/10.1016/S0140-6736(10)60406-0.

EASD Virtual Meeting (no date). Available at: http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-sglt2-inhibitors-in-patients-with-type-2-diabetes-mellitus.

‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’ (2008) New England Journal of Medicine, 358(24), pp. 2545–2559. Available at: https://doi.org/10.1056/NEJMoa0802743.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743.

‘Efficacy and Safety of Glucagon-like peptide-1 receptor agonists  in type 2 diabetes  Systematic review and mixed-treatment comparison analysis’ (no date). Available at: http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf.

Eng, C. et al. (2014) ‘Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis’, The Lancet, 384(9961), pp. 2228–2234. Available at: https://doi.org/10.1016/S0140-6736(14)61335-0.

Evans, M. et al. (2011) ‘A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations’, Diabetes, Obesity and Metabolism, 13(8), pp. 677–684. Available at: https://doi.org/10.1111/j.1463-1326.2011.01395.x.

F Game (2012) ‘Annals of The Royal College of Surgeons of England’, 94(5). Available at: https://doi.org/doi:  10.1308/003588412X13171221591655.

Fineman, M.S. et al. (2012) ‘GLP-1 based therapies: differential effects on fasting and postprandial glucose’, Diabetes, Obesity and Metabolism, 14(8), pp. 675–688. Available at: https://doi.org/10.1111/j.1463-1326.2012.01560.x.

Frandsen, C.S.S. and Madsbad, S. (2014a) ‘Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review’, Diabetic Medicine, 31(11), pp. 1293–1300. Available at: https://doi.org/10.1111/dme.12561.

Frandsen, C.S.S. and Madsbad, S. (2014b) ‘Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review’, Diabetic Medicine, 31(11), pp. 1293–1300. Available at: https://doi.org/10.1111/dme.12561.

Frisch, A. et al. (2010) ‘Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery’, Diabetes Care, 33(8), pp. 1783–1788. Available at: https://doi.org/10.2337/dc10-0304.

Fullerton, B. et al. (1996) ‘Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD009122.pub2.

Garber, A.J. et al. (2006) ‘Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)’, Diabetes, Obesity and Metabolism, 8(1), pp. 58–66. Available at: https://doi.org/10.1111/j.1463-1326.2005.00563.x.

Garber, A.J. et al. (2007) ‘Premixed insulin treatment for type 2 diabetes: analogue or human?’, Diabetes, Obesity and Metabolism, 9(5), pp. 630–639. Available at: https://doi.org/10.1111/j.1463-1326.2006.00654.x.

Giugliano, D. et al. (2011) ‘Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials’, Diabetes Care, 34(2), pp. 510–517. Available at: https://doi.org/10.2337/dc10-1710.

Goudswaard, A.N. et al. (1996) ‘Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD003418.pub2.

Gough, S.C.L. et al. (2013) ‘Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial’, Diabetes Care, 36(9), pp. 2536–2542. Available at: https://doi.org/10.2337/dc12-2329.

Gregory T. Mucha,Stacia Merkel,William Thomas,John P. Bantle (no date) ‘Fasting and insulin glargine in individuals with type 1 diabetes’, Diabetes Care [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=17&amp;docId=GALE%7CA116666633&amp;docType=Article&amp;sort=Relevance&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA116666633&amp;searchId=R8&amp;userGroupName=leicester&amp;inPS=true.

Guevara-Aguirre, J. et al. (2004) ‘Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents’, Diabetes Technology & Therapeutics, 6(1), pp. 1–8. Available at: https://doi.org/10.1089/152091504322783341.

Gururaj Setty, S. et al. (2016) ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, 92(1085), pp. 152–164. Available at: https://doi.org/10.1136/postgradmedj-2015-133716.

Gurwitz, J.H. (1994) ‘Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy’, Archives of Internal Medicine, 154(1). Available at: https://doi.org/10.1001/archinte.1994.00420010131015.

Hannele Yki-Järvinen (2013) ‘Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?’, Diabetes Care, 36(Suppl 2). Available at: https://doi.org/doi:  10.2337/dcS13-2026.

Hannele Yki-Jarvinen,Leena Juurinen,Michael Alvarsson,Tord Bystedt,Ian Caldwell,Melanie Davies (no date) ‘Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups’, Diabetes Care [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&amp;docType=Clinical+report&amp;tabID=T002&amp;prodId=EAIM&amp;searchId=R1&amp;resultListType=RESULT_LIST&amp;searchType=AdvancedSearchForm&amp;contentSegment=&amp;currentPosition=5&amp;searchResultsType=SingleTab&amp;inPS=true&amp;userGroupName=leicester&amp;docId=GALE%7CA165017903&amp;contentSet=GALE%7CA165017903.

Heller, S. et al. (2012) ‘Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial’, The Lancet, 379(9825), pp. 1489–1497. Available at: https://doi.org/10.1016/S0140-6736(12)60204-9.

Heller, S.R. et al. (2004) ‘Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes’, Diabetic Medicine, 21(7), pp. 769–775. Available at: https://doi.org/10.1111/j.1464-5491.2004.01244.x.

Hermansen, K. et al. (2006) ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’, Diabetes Care, 29(6), pp. 1269–1274. Available at: https://doi.org/10.2337/dc05-1365.

Hermansen, K. and Davies, M. (2007) ‘Does insulin detemir have a role in reducing risk of insulin-associated weight gain?’, Diabetes, Obesity and Metabolism, 9(3), pp. 209–217. Available at: https://doi.org/10.1111/j.1463-1326.2006.00665.x.

Hirsch, I.B. et al. (2014) ‘Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy’, Diabetes, Obesity and Metabolism, 16(3), pp. 206–214. Available at: https://doi.org/10.1111/dom.12136.

Hirsch, I.B. et al. (2017) ‘Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST                              T1)’, Diabetic Medicine, 34(2), pp. 167–173. Available at: https://doi.org/10.1111/dme.13068.

Holman, R.R. et al. (2007a) ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, 357(17), pp. 1716–1730. Available at: https://doi.org/10.1056/NEJMoa075392.

Holman, R.R. et al. (2007b) ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, 357(17), pp. 1716–1730. Available at: https://doi.org/10.1056/NEJMoa075392.

Holman, R.R. et al. (2008) ‘10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes’, New England Journal of Medicine, 359(15), pp. 1577–1589. Available at: https://doi.org/10.1056/NEJMoa0806470.

Holman, R.R. et al. (2009a) ‘Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes’, New England Journal of Medicine, 361(18), pp. 1736–1747. Available at: https://doi.org/10.1056/NEJMoa0905479.

Holman, R.R. et al. (2009b) ‘Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes’, New England Journal of Medicine, 361(18), pp. 1736–1747. Available at: https://doi.org/10.1056/NEJMoa0905479.

Holman, R.R. et al. (2009c) ‘Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes’, New England Journal of Medicine, 361(18), pp. 1736–1747. Available at: https://doi.org/10.1056/NEJMoa0905479.

Holman, R.R. and Turner, R.C. (1985) ‘A Practical Guide to Basal and Prandial Insulin Therapy’, Diabetic Medicine, 2(1), pp. 45–53. Available at: https://doi.org/10.1111/j.1464-5491.1985.tb00592.x.

Holt, R.I.G. (2010a) Textbook of diabetes. 4th ed. Chichester: Wiley-Blackwell. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077.

Holt, R.I.G. (2010b) Textbook of diabetes. 4th ed. Chichester: Wiley-Blackwell. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077.

Holt, R.I.G. et al. (2016a) Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated. Available at: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056.

Holt, R.I.G. et al. (2016b) Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated. Available at: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056.

Home, P. et al. (2014) ‘Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?’, Diabetes Care, 37(6), pp. 1499–1508. Available at: https://doi.org/10.2337/dc13-2743.

Home, P.D. (2012) ‘The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences’, Diabetes, Obesity and Metabolism, 14(9), pp. 780–788. Available at: https://doi.org/10.1111/j.1463-1326.2012.01580.x.

Home, P.D. et al. (2015) ‘New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)’, Diabetes Care, 38(12), pp. 2217–2225. Available at: https://doi.org/10.2337/dc15-0249.

Hommel, I. et al. (2015) ‘Perioperative diabetes care: room for improving the person centredness’, Diabetic Medicine, 32(4), pp. 561–568. Available at: https://doi.org/10.1111/dme.12600.

Horvath, K. et al. (1996a) ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD005613.pub3.

Horvath, K. et al. (1996b) ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD005613.pub3.

Hui, E. et al. (2010a) ‘Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan’, International Journal of Clinical Practice, 64(8), pp. 1095–1099. Available at: https://doi.org/10.1111/j.1742-1241.2010.02347.x.

Hui, E. et al. (2010b) ‘Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan’, International Journal of Clinical Practice, 64(8), pp. 1095–1099. Available at: https://doi.org/10.1111/j.1742-1241.2010.02347.x.

Hwang, J.L. and Weiss, R.E. (2014) ‘Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment’, Diabetes/Metabolism Research and Reviews, 30(2), pp. 96–102. Available at: https://doi.org/10.1002/dmrr.2486.

‘Hyperglycemia and Adverse Pregnancy Outcomes’ (2008) New England Journal of Medicine, 358(19), pp. 1991–2002. Available at: https://doi.org/10.1056/NEJMoa0707943.

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study (no date). Available at: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html.

Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI (no date). Available at: http://www.ncbi.nlm.nih.gov/pubmed/17102158.

Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873.

Ismail-Beigi, F. (2012) ‘Glycemic Management of Type 2 Diabetes Mellitus’, New England Journal of Medicine, 366(14), pp. 1319–1327. Available at: https://doi.org/10.1056/NEJMcp1013127.

Jackson, M.J. et al. (2016) ‘Perioperative management of diabetes in elective patients: a region-wide audit’, British Journal of Anaesthesia, 116(4), pp. 501–506. Available at: https://doi.org/10.1093/bja/aev554.

Jenkins, K. (2014) ‘II. Needle phobia: a psychological perspective’, British Journal of Anaesthesia, 113(1), pp. 4–6. Available at: https://doi.org/10.1093/bja/aeu013.

June James (no date) ‘End-of-life care: Anything but a pathway’. Available at: http://www.diabetesandprimarycare.co.uk/media/content/_master/3572/files/pdf/dpc15-6-292-7.pdf.

June James (no date) ‘Safety and insulin: implementation of national guidance at a local level’, Journal of Diabetes Nursing [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=8&amp;docId=GALE%7CA342482979&amp;docType=Article&amp;sort=RELEVANCE&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA342482979&amp;searchId=R6&amp;userGroupName=leicester&amp;inPS=true.

Kahler, P. et al. (2014) ‘Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials’, BMJ Open, 4(8), pp. e004806–e004806. Available at: https://doi.org/10.1136/bmjopen-2014-004806.

Khedkar, A. et al. (2010) ‘A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects’, Diabetes, Obesity and Metabolism, 12(8), pp. 659–664. Available at: https://doi.org/10.1111/j.1463-1326.2010.01213.x.

Kramer, C.K., Zinman, B. and Retnakaran, R. (2013) ‘Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis’, The Lancet Diabetes & Endocrinology, 1(1), pp. 28–34. Available at: https://doi.org/10.1016/S2213-8587(13)70006-8.

Kuhlmann, M. and Marre, M. (2010) ‘Lessons learned from biosimilar epoetins and insulins’, The British Journal of Diabetes & Vascular Disease, 10(2), pp. 90–97. Available at: https://doi.org/10.1177/1474651409355454.

Kutz, A. et al. (2017) ‘The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13325.

L. Luzi (1989) ‘Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans’, American Journal of Physiology - Endocrinology and Metabolism, 257(2), pp. E241–E246. Available at: http://ajpendo.physiology.org.ezproxy4.lib.le.ac.uk/content/257/2/E241.

Lambert, K. and Holt, R.I.G. (2013) ‘The use of insulin analogues in pregnancy’, Diabetes, Obesity and Metabolism, 15(10), pp. 888–900. Available at: https://doi.org/10.1111/dom.12098.

Lankisch, M.R. et al. (2008) ‘Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs’, Diabetes, Obesity and Metabolism [Preprint]. Available at: https://doi.org/10.1111/j.1463-1326.2008.00967.x.

Lasserson, D.S. et al. (2009a) ‘Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses’, Diabetologia, 52(10), pp. 1990–2000. Available at: https://doi.org/10.1007/s00125-009-1468-7.

Lasserson, D.S. et al. (2009b) ‘Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses’, Diabetologia, 52(10), pp. 1990–2000. Available at: https://doi.org/10.1007/s00125-009-1468-7.

Lea, Mary R.      Creme, Phyllis (2008) Writing At University. 3rd edn. McGraw-Hill Education. Available at: http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=345134.

Levy, N., Penfold, N. and Mythen, M. (2016) ‘Perioperative management of diabetes and the emerging role of anaesthetists as perioperative physicians’, British Journal of Anaesthesia, 116(4), pp. 443–447. Available at: https://doi.org/10.1093/bja/aew049.

Liu, D. et al. (2013) ‘A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy’, Allergy, Asthma & Clinical Immunology, 9(1). Available at: https://doi.org/10.1186/1710-1492-9-30.

Luc JC van Loon (2000) ‘Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate’, The American Journal of Clinical Nutrition, 72(1), pp. 96–105. Available at: http://ajcn.nutrition.org/content/72/1/96.full.

Luzio, S.D. et al. (2010) ‘The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes’, Diabetes, Obesity and Metabolism, 12(1), pp. 82–87. Available at: https://doi.org/10.1111/j.1463-1326.2009.01146.x.

Manju Chandran,Steven V. Edelman (no date) ‘Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers)’, Clinical Diabetes [Preprint]. Available at: http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=3&amp;docId=GALE%7CA100730300&amp;docType=Article&amp;sort=Relevance&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA100730300&amp;searchId=R2&amp;userGroupName=leicester&amp;inPS=true.

Martha M. Funnell (no date) ‘Overcoming barriers to the initiation of insulin therapy’, Clinical Diabetes [Preprint]. Available at: http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&amp;docType=Article&amp;tabID=T002&amp;prodId=EAIM&amp;searchId=R1&amp;resultListType=RESULT_LIST&amp;searchType=AdvancedSearchForm&amp;contentSegment=&amp;currentPosition=8&amp;searchResultsType=SingleTab&amp;inPS=true&amp;userGroupName=leicester&amp;docId=GALE%7CA159389875&amp;contentSet=GALE%7CA159389875.

Matthew C. Riddle,Julio Rosenstock,John Gerich (no date) ‘The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients’, Diabetes Care [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=9&amp;docId=GALE%7CA110470954&amp;docType=Article&amp;sort=Relevance&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA110470954&amp;searchId=R3&amp;userGroupName=leicester&amp;inPS=true.

Mattoo, V. et al. (2003) ‘A comparison of insulin lispro Mix25^TM and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan’, Diabetes Research and Clinical Practice, 59(2), pp. 137–143. Available at: https://doi.org/10.1016/S0168-8227(02)00202-4.

McBain, H. et al. (2017) ‘Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study’, Diabetic Medicine, 34(2), pp. 253–261. Available at: https://doi.org/10.1111/dme.13196.

McCrimmon, R.J. (2017) ‘Old habits are hard to break: lessons from the study of hypoglycaemia’, Diabetic Medicine, 34(2), pp. 148–155. Available at: https://doi.org/10.1111/dme.13277.

Menting, J.G. et al. (2013) ‘How insulin engages its primary binding site on the insulin receptor’, Nature, 493(7431), pp. 241–245. Available at: https://doi.org/10.1038/nature11781.

Mollema, E.D. et al. (2001) ‘Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening’, Diabetic Medicine, 18(8), pp. 671–674. Available at: https://doi.org/10.1046/j.1464-5491.2001.00547.x.

Morçöl, T. et al. (2004) ‘Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin’, International Journal of Pharmaceutics, 277(1–2), pp. 91–97. Available at: https://doi.org/10.1016/j.ijpharm.2003.07.015.

Nathan, D.M. et al. (2006) ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, 29(8), pp. 1963–1972. Available at: https://doi.org/10.2337/dc06-9912.

Nathan, D.M. (2014) ‘The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview’, Diabetes Care, 37(1), pp. 9–16. Available at: https://doi.org/10.2337/dc13-2112.

Nauck, M. (2016) ‘Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Diabetes, Obesity and Metabolism, 18(3), pp. 203–216. Available at: https://doi.org/10.1111/dom.12591.

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes (no date). Available at: http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/.

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086.

Owens, D.R. et al. (2011) ‘Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study’, Diabetes, Obesity and Metabolism, 13(11), pp. 1020–1027. Available at: https://doi.org/10.1111/j.1463-1326.2011.01459.x.

Owens, D.R. (2013) ‘Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice’, Diabetic Medicine, 30(3), pp. 276–288. Available at: https://doi.org/10.1111/dme.12019.

P. Schneiter (1998) ‘Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans’, American Journal of Physiology - Endocrinology and Metabolism, 275(5), pp. E806–E813. Available at: http://ajpendo.physiology.org/content/275/5/E806.

Park, S.W. et al. (2017) ‘Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST                              : SIMPLE USE)’, Diabetic Medicine, 34(2), pp. 174–179. Available at: https://doi.org/10.1111/dme.13069.

Peter Mansell (no date) ‘The dose adjustment for normal eating (DAFNE) education programme’, Journal of Diabetes Nursing [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=1&amp;docId=GALE%7CA314268073&amp;docType=Article&amp;sort=Relevance&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA314268073&amp;searchId=R1&amp;userGroupName=leicester&amp;inPS=true.

Philip Raskin,Elsie Allen,Priscilla Hollander,Andrew Lewin,Robert A. Gabbay,Peter Hu (no date) ‘Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs’, Diabetes Care [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&amp;docType=Article&amp;tabID=T002&amp;prodId=EAIM&amp;searchId=R5&amp;resultListType=RESULT_LIST&amp;searchType=AdvancedSearchForm&amp;contentSegment=&amp;currentPosition=5&amp;searchResultsType=SingleTab&amp;inPS=true&amp;userGroupName=leicester&amp;docId=GALE%7CA128867472&amp;contentSet=GALE%7CA128867472.

Pickup, J.C., Reznik, Y. and Sutton, A.J. (2017) ‘Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials’, Diabetes Care, 40(5), pp. 715–722. Available at: https://doi.org/10.2337/dc16-2201.

Pozzilli, P. et al. (2005) ‘Biokinetics of buccal spray insulin in patients with type 1 diabetes’, Metabolism, 54(7), pp. 930–934. Available at: https://doi.org/10.1016/j.metabol.2005.02.008.

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320.

‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’ (4AD). Available at: https://www.youtube.com/watch?v=AhhWTmEFuag.

Raccah, D., Huet, D., Dib, A, et al. (2017a) ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13390.

Raccah, D., Huet, D., Dib, A, et al. (2017b) ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13390.

Raccah, D., Huet, D., Dib, A., et al. (2017a) ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine, 34(9), pp. 1193–1204. Available at: https://doi.org/10.1111/dme.13390.

Raccah, D., Huet, D., Dib, A., et al. (2017b) ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine, 34(9), pp. 1193–1204. Available at: https://doi.org/10.1111/dme.13390.

Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931.

Richter, B. and Neises, G. (1996) ‘“Human” insulin versus animal insulin in people with diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD003816.pub2.

Riddle, M.C. et al. (2013) ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)’, Diabetes Care, 36(9), pp. 2489–2496. Available at: https://doi.org/10.2337/dc12-2454.

Riddle, Matthew C. et al. (2014) ‘New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)’, Diabetes Care, 37(10), pp. 2755–2762. Available at: https://doi.org/10.2337/dc14-0991.

Riddle, M. C. et al. (2014) ‘Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections’, Diabetes, Obesity and Metabolism, 16(5), pp. 396–402. Available at: https://doi.org/10.1111/dom.12225.

Rodbard, H.W. et al. (2017) ‘Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial’, Diabetic Medicine, 34(2), pp. 189–196. Available at: https://doi.org/10.1111/dme.13256.

Rorsman, P. and Renstr�m, E. (2003) ‘Insulin granule dynamics in pancreatic beta cells’, Diabetologia, 46(8), pp. 1029–1045. Available at: https://doi.org/10.1007/s00125-003-1153-1.

Rosenstock, J., Bergenstal, R.M., et al. (2013) ‘Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study’, Diabetes Care, 36(3), pp. 522–528. Available at: https://doi.org/10.2337/dc12-0067.

Rosenstock, J., Raccah, D., et al. (2013) ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)’, Diabetes Care, 36(10), pp. 2945–2951. Available at: https://doi.org/10.2337/dc12-2709.

Rosenstock, J. et al. (2014a) ‘Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes’, Diabetes Care, 37(7), pp. 1815–1823. Available at: https://doi.org/10.2337/dc13-3055.

Rosenstock, J. et al. (2014b) ‘Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes’, Diabetes Care, 37(7), pp. 1815–1823. Available at: https://doi.org/10.2337/dc13-3055.

Rowles, S., Kilvert, A. and Sinclair, A. (2011a) ‘ABCD position statement on diabetes and end of life care’, Practical Diabetes International, 28(1), pp. 26–27. Available at: https://doi.org/10.1002/pdi.1547.

Rowles, S., Kilvert, A. and Sinclair, A. (2011b) ‘ABCD position statement on diabetes and end of life care’, Practical Diabetes International, 28(1), pp. 26–27. Available at: https://doi.org/10.1002/pdi.1547.

Russell-Jones, D. and Khan, R. (2007) ‘Insulin-associated weight gain in diabetes – causes, effects and coping strategies’, Diabetes, Obesity and Metabolism, 9(6), pp. 799–812. Available at: https://doi.org/10.1111/j.1463-1326.2006.00686.x.

Shosuke Satake,Mary Courtney Moore,Kayano Igawa,Margaret Converse,Benjamin Farmer,Doss W. Neal (no date) ‘Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles)’, Diabetes [Preprint]. Available at: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&amp;resultListType=RESULT_LIST&amp;searchResultsType=SingleTab&amp;searchType=AdvancedSearchForm&amp;currentPosition=2&amp;docId=GALE%7CA87347789&amp;docType=Article&amp;sort=Relevance&amp;contentSegment=&amp;prodId=EAIM&amp;contentSet=GALE%7CA87347789&amp;searchId=R8&amp;userGroupName=leicester&amp;inPS=true.

Simmons, J.H. et al. (2007) ‘Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes’, Diabetes Care, 30(4), pp. 987–988. Available at: https://doi.org/10.2337/dc06-1553.

Simmons, L.R. et al. (2012) ‘Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes?’, ISRN Endocrinology, 2012, pp. 1–5. Available at: https://doi.org/10.5402/2012/910905.

Srinivasan, B.T. et al. (2008) ‘Recent advances in the management of type 2 diabetes mellitus: a review’, Postgraduate Medical Journal, 84(996), pp. 524–531. Available at: https://doi.org/10.1136/pgmj.2008.067918.

Srinivasan, B.T. and Davies, M. (2014) ‘Glycaemic management of type 2 diabetes’, Medicine, 42(12), pp. 711–717. Available at: https://doi.org/10.1016/j.mpmed.2014.09.011.

Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737.

Swinnen, S.G. et al. (1996) ‘Insulin detemir versus insulin glargine for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD006383.pub2.

Tapley, M. and Needham, E. (2012) ‘Improving end of life care for people with diabetes’, Practical Diabetes, 29(8), pp. 306–307a. Available at: https://doi.org/10.1002/pdi.1711.

‘The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus’ (1993) New England Journal of Medicine, 329(14), pp. 977–986. Available at: https://doi.org/10.1056/NEJM199309303291401.

Tikkanen-Dolenc, H. et al. (2016) ‘Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes’, Diabetologia [Preprint]. Available at: https://doi.org/10.1007/s00125-016-4189-8.

‘Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial’ (2002) BMJ, 325(7367), pp. 746–746. Available at: https://doi.org/10.1136/bmj.325.7367.746.

Villani, M., de Courten, B. and Zoungas, S. (2017) ‘Emergency treatment of hypoglycaemia: a guideline and evidence review’, Diabetic Medicine, 34(9), pp. 1205–1211. Available at: https://doi.org/10.1111/dme.13379.

W. Blair Geho (2014) ‘A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus’, Journal of Diabetes Science and Technology, 8(3). Available at: https://doi.org/doi:  10.1177/1932296814524871.

Wahren, J. and Kallas, A. (2012) ‘Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?’, Diabetes, 61(9), pp. 2228–2229. Available at: https://doi.org/10.2337/db12-0664.

Walker, R.A., Rodgers, J., and Diabetes UK. (2010) Diabetes: a practical guide to managing your health. Fully revised and updated. London: Dorling Kindersley.

Wang, C., Mamza, J. and Idris, I. (2015) ‘Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials’, Diabetic Medicine, 32(5), pp. 585–594. Available at: https://doi.org/10.1111/dme.12694.

Wang, W. et al. (2017) ‘Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis’, Diabetes Therapy [Preprint]. Available at: https://doi.org/10.1007/s13300-017-0282-3.

Yki-Jarvinen, H. et al. (2007) ‘Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups’, Diabetes Care, 30(6), pp. 1364–1369. Available at: https://doi.org/10.2337/dc06-1357.

Yki-Jarvinen, H. and Kotronen, A. (2013) ‘Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?’, Diabetes Care, 36(Supplement_2), pp. S205–S211. Available at: https://doi.org/10.2337/dcS13-2026.

Young, L.A. and Buse, J.B. (2014) ‘GLP-1 receptor agonists and basal insulin in type 2 diabetes’, The Lancet, 384(9961), pp. 2180–2181. Available at: https://doi.org/10.1016/S0140-6736(14)61409-4.

Zambanini, A. et al. (1999) ‘Injection related anxiety in insulin-treated diabetes’, Diabetes Research and Clinical Practice, 46(3), pp. 239–246. Available at: https://doi.org/10.1016/S0168-8227(99)00099-6.

Zinman, B. et al. (2011) ‘Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial’, The Lancet, 377(9769), pp. 924–931. Available at: https://doi.org/10.1016/S0140-6736(10)62305-7.